Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/73787
Campo DC Valoridioma
dc.contributor.authorCarmona-Bayonas, Albertoen_US
dc.contributor.authorJiménez-Fonseca, Paulaen_US
dc.contributor.authorEchaburu, Juan Virizuelaen_US
dc.contributor.authorAntonio, Maiteen_US
dc.contributor.authorFont, Carmeen_US
dc.contributor.authorBiosca, Mercèen_US
dc.contributor.authorRamchandani, Avinashen_US
dc.contributor.authorMartínez, Jerónimoen_US
dc.contributor.authorCubero, Jorge Hernandoen_US
dc.contributor.authorEspinosa, Javieren_US
dc.contributor.authorDe Castro, Eva Martínezen_US
dc.contributor.authorGhanem, Ismaelen_US
dc.contributor.authorBeato, Carmenen_US
dc.contributor.authorBlasco, Anaen_US
dc.contributor.authorGarrido, Marceloen_US
dc.contributor.authorBonilla, Yaizaen_US
dc.contributor.authorMondéjar, Rebecaen_US
dc.contributor.authorLanza, María Ángeles Arcusaen_US
dc.contributor.authorManrique, Isabel Aragónen_US
dc.contributor.authorManzano, Aránzazuen_US
dc.contributor.authorSevillano, Elenaen_US
dc.contributor.authorCastañón, Eduardoen_US
dc.contributor.authorCardona, Mercéen_US
dc.contributor.authorMartín, Elena Gallardoen_US
dc.contributor.authorArmillas, Quionia Pérezen_US
dc.contributor.authorLasheras, Fernando Sánchezen_US
dc.contributor.authorDe La Peña, Francisco Ayalaen_US
dc.date.accessioned2020-07-24T08:40:59Z-
dc.date.available2020-07-24T08:40:59Z-
dc.date.issued2015en_US
dc.identifier.issn0732-183Xen_US
dc.identifier.otherScopus-
dc.identifier.urihttp://hdl.handle.net/10553/73787-
dc.description.abstractPurpose: To validate a prognostic score predicting major complications in patients with solid tumors and seemingly stable episodes of febrile neutropenia (FN). The definition of clinical stability implies the absence of organ dysfunction, abnormalities in vital signs, and major infections. Patients and Methods: We developed the Clinical Index of Stable Febrile Neutropenia (CISNE), with six explanatory variables associated with serious complications: Eastern Cooperative Oncology Group performance status ≥ 2 (2 points), chronic obstructive pulmonary disease (1 point), chronic cardiovascular disease (1 point), mucositis of grade ≥ 2 (National Cancer Institute Common Toxicity Criteria; 1 point), monocytes < 200 per μL (1 point), and stress-induced hyperglycemia (2 points). We ntegrated these factors into a score ranging from 0 to 8, which classifies patients into three prognostic classes: low (0 points), intermediate (1 to 2 points), and high risk (≥ 3 points). We present a multicenter validation of CISNE. Results: We prospectively recruited 1,133 patients with seemingly stable FN from 25 hospitals. Complication rates in the training and validation subsets, respectively, were 1.1% and 1.1% in low-, 6.1% and 6.2% in intermediate-, and 32.5% and 36% in high-risk patients; mortality rates within each class were 0% in low-, 1.6% and 0% in intermediate-, and 4.3% and 3.1% in high-risk patients. Areas under the receiver operating characteristic curves in the validation subset were 0.652 (95% CI, 0.598 to 0.703) for Talcott, 0.721 (95% CI, 0.669 to 0.768) for Multinational Association for Supportive Care in Cancer (MASCC), and 0.868 (95% CI, 0.827 to 0.903) for CISNE (P = .002 for comparison between CISNE and MASCC). Conclusion: CISNE is a valid model for accurately classifying patients with cancer with seemingly stable FN episodes.en_US
dc.languageengen_US
dc.relation.ispartofJournal of Clinical Oncologyen_US
dc.sourceJournal of Clinical Oncology [ISSN 0732-183X], v. 33 (5), p. 465-471, (Febrero 2015)en_US
dc.subject320101 Oncologíaen_US
dc.titlePrediction of serious complications in patients with seemingly stable febrile neutropenia: Validation of the clinical index of stable febrile neutropenia in a prospective cohort of patients from the FINITE studyen_US
dc.typeinfo:eu-repo/semantics/Articleen_US
dc.typeArticleen_US
dc.identifier.doi10.1200/JCO.2014.57.2347en_US
dc.identifier.scopus84922390763-
dc.contributor.authorscopusid36962083000-
dc.contributor.authorscopusid24587475200-
dc.contributor.authorscopusid56507534600-
dc.contributor.authorscopusid7005746488-
dc.contributor.authorscopusid7004724913-
dc.contributor.authorscopusid57159691800-
dc.contributor.authorscopusid25927453400-
dc.contributor.authorscopusid7404311816-
dc.contributor.authorscopusid56506718400-
dc.contributor.authorscopusid57213689182-
dc.contributor.authorscopusid56506700000-
dc.contributor.authorscopusid36621755300-
dc.contributor.authorscopusid56395294700-
dc.contributor.authorscopusid15755158800-
dc.contributor.authorscopusid24168617200-
dc.contributor.authorscopusid56507220900-
dc.contributor.authorscopusid56507059600-
dc.contributor.authorscopusid56506562200-
dc.contributor.authorscopusid6602453487-
dc.contributor.authorscopusid55218483600-
dc.contributor.authorscopusid57082663500-
dc.contributor.authorscopusid6602444419-
dc.contributor.authorscopusid56506450000-
dc.contributor.authorscopusid56506119500-
dc.contributor.authorscopusid56507466000-
dc.contributor.authorscopusid35210989000-
dc.contributor.authorscopusid55673452100-
dc.identifier.eissn1527-7755-
dc.description.lastpage471en_US
dc.identifier.issue5-
dc.description.firstpage465en_US
dc.relation.volume33en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.utils.revisionen_US
dc.date.coverdateFebrero 2015en_US
dc.identifier.ulpgces
dc.description.sjr9,134
dc.description.sjrqQ1
dc.description.scieSCIE
item.fulltextSin texto completo-
item.grantfulltextnone-
Colección:Artículos
Vista resumida

Citas SCOPUSTM   

119
actualizado el 30-mar-2025

Citas de WEB OF SCIENCETM
Citations

102
actualizado el 30-mar-2025

Visitas

79
actualizado el 10-ago-2024

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.